Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD

Otsuka

Status: Completed

Conditions: Polycystic Kidney, Autosomal Dominant

Treatments: Drug: tolvaptan

Study type: Observational

Funder types: Industry

Identifiers

NCT02847624

15600-003

Details and patient eligibility

About

The purpose of this study is to evaluate the safety and effectiveness of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD) in the real world clinical setting in Japan.

Enrollment: 1,672 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• diagnosed ADPKD
• total kidney volume of 750 or more

Exclusion criteria

Trial design

1,672 participants in 1 patient group

ADPKD

Treatment:

Drug: tolvaptan